Skip to content

China type 2 diabetes complications prevention study

Intervention study on type 2 diabetes and its complications

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-PRC-08000234
Enrollment
Unknown
Registered
2008-12-01
Start date
2002-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Group A:Intensive control of blood glucose and pressure
Group B:Intensive control of blood glucose, lipids and blood pressure
Group C:intensive control of blood glucose (with rosiglitazone sodium single or combined treatment), lipids and blood pressure
Group D:Intensive control of blood glucose, lipids and blood pressure, combined the treatment of compound Danshen Di Wan
Group E:(IMT>1.3mm) intensive control of blood glucose, lipids and blood pressure
Group F:control group (IMT<1.2mm), random treatment in outpatient department
Group G:control group (IMT without limit), random treatment in outpatient department

Sponsors

Beijing Hospital of China Ministry of Health
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. New diagnosed type 2 diabetes within one year, stable diet and medicine treatment over 2 weeks; 2. Aged from 35 to 75 years old, no limit on gender; 3. BMI within 19 to 35/kg/m2; 4. IMT1.3mm in group E, group F has no limit of IMT; 5. No ketosis and other stress condition within half one year; 6. Former treatment including TZD, Vit E and compound Dan Shen should stop and pass the 4-week elution; 7. Good compliance and willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Course of diabetes over 1 year; 2. Combined the overt coronary, cerebral, kidney and peripheral artery disease, or IMT over the above range; 3. Serum Cr is over 1.2 times normal range, ALT is over 2 times normal range; 4. Combined the ketosis or ketoacidosis, sever stress condition within half an year; 5. Abnormal gastrointestinal absorption; 6. Female in pregnant or breast-feeding;

Design outcomes

Primary

MeasureTime frame
IMT;clinical overt macrovascular disease;

Secondary

MeasureTime frame
retinopathy;LDL-c, TC, TG;HbA1c, fasting serum glucose;SBP, DBP;urina sanguinis albumin/creatinin;

Countries

China

Contacts

Public ContactWang Yao

Beijing Hospital of China Ministry of Health

wangyao59918@yahoo.com.cn+86 010 85137808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026